PMID- 34046363
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230920
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management 
      in Relapsed and Refractory Multiple Myeloma.
PG  - 678634
LID - 10.3389/fonc.2021.678634 [doi]
LID - 678634
AB  - Belantamab mafodotin (belamaf), an antibody-drug conjugate approved for the 
      treatment of relapsed and refractory multiple myeloma (RRMM), is an anti B-cell 
      maturation antigen (BCMA) agent. DREAMM-1, a first in-human trial of belamaf, 
      reported several ocular toxicities requiring dose adjustments, dose delays and 
      treatment discontinuations. In DREAMM-1, 53% of patients in part-1 and 63% of 
      patients in part-2 had ocular toxicity. Similarly, 73% of patients in DREAMM-2 
      had keratopathy (71% in 2.5 mg/kg versus 75% in 3.4 mg/kg) with the most common 
      symptoms being blurred vision and dry eyes. Ocular toxicity of belamaf is 
      attributed to microtubule-disrupting monomethylauristatin-F (MMAF), a cytotoxic 
      payload of the drug that causes an off-target damage to the corneal epithelial 
      cells. Ocular adverse events (AEs) of belamaf are more frequent at higher doses 
      compared with lower doses. Higher belamaf dose, history of dry eyes and soluble 
      BCMA are associated with increased risk of corneal toxicity. Absence of ocular 
      symptoms does not exclude the possibility of belamaf-induced ocular toxicity, so 
      patients need slit lamp and Snellen visual acuity testing to detect 
      microcytic-like epithelial changes and visual decline. Corticosteroid eyes drops 
      for 4-7 days prior to belamaf dose do not prevent ocular AEs and may cause 
      steroid-related AEs instead. Keratopathy and Visual Acuity scale (KVA) is 
      recommended to document the severity of belamaf-induced ocular toxicity and make 
      treatment adjustments. Management of toxicity includes dosage modifications, 
      treatment interruption or discontinuations and preservative-free artificial tears 
      along with close ophthalmology and hematology-oncology follow-ups.
CI  - Copyright (c) 2021 Wahab, Rafae, Mushtaq, Masood, Ehsan, Khakwani and Khan.
FAU - Wahab, Ahsan
AU  - Wahab A
AD  - Internal Medicine/Hospital Medicine Department, University of Alabama at 
      Birmingham, Montgomery, AL, United States.
FAU - Rafae, Abdul
AU  - Rafae A
AD  - Internal Medicine Residency Program, McLaren Regional Medical Center, Flint, MI, 
      United States.
FAU - Mushtaq, Kamran
AU  - Mushtaq K
AD  - Internal Medicine/Hospital Medicine Department, Northeast Internal Medicine 
      Associates, LaGrange, IN, United States.
FAU - Masood, Adeel
AU  - Masood A
AD  - Hospital Medicine, TidalHealth Peninsula Regional, Salisbury, MD, United States.
FAU - Ehsan, Hamid
AU  - Ehsan H
AD  - Biomedical Sciences/Biohazardous Threat Agents & Emerging Infectious Diseases 
      Department, Georgetown University, Washington, DC, United States.
FAU - Khakwani, Maria
AU  - Khakwani M
AD  - Department of Medicine, Lahore Medical and Dental College, Lahore, Pakistan.
FAU - Khan, Aqsa
AU  - Khan A
AD  - Department of Medicine, Fatima Jinnah Medical University, Lahore, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210511
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8148346
OTO - NOTNLM
OT  - B-cell maturation antigen
OT  - belantamab mafodotin
OT  - management
OT  - multiple myeloma
OT  - ocular toxicity
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/05/29 06:00
MHDA- 2021/05/29 06:01
PMCR- 2021/01/01
CRDT- 2021/05/28 07:28
PHST- 2021/03/10 00:00 [received]
PHST- 2021/04/23 00:00 [accepted]
PHST- 2021/05/28 07:28 [entrez]
PHST- 2021/05/29 06:00 [pubmed]
PHST- 2021/05/29 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.678634 [doi]
PST - epublish
SO  - Front Oncol. 2021 May 11;11:678634. doi: 10.3389/fonc.2021.678634. eCollection 
      2021.